

SEP 11 1998  
PATENT & TRADEMARK OFFICE

FORM PTO-1449  
(REV. 7-80)ATTY. DOCKET NO.  
NYU93-01M4AZSERIAL NO.  
09/133,119INFORMATION DISCLOSURE CITATION  
IN AN APPLICATIONAPPLICANT  
Junming Le et al.FILING DATE  
August 12, 1998GROUP  
1642

SEP 11 1998

## FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
KAC	AL2	0398327A1	22 NOV 90	EPO			
	AM2	0412486A1	13 FEB 91	EPO			
	AN2	0433900A1	26 JUN 91	EPO			
	AO2	0526905A2	10 FEB 93	EPO			
	AP2	WO91/02078	21 FEB 91	PCT			
✓	AQ2	WO92/07076	30 APR 92	PCT			

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AU	Liang, Chi-Ming et al., "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," <i>Biochem. &amp; Biophys. Res. Comm.</i> , 137(2):847-854 (1986).
	AV	Hirai, Makoto et al., "Production and characterization of monoclonal antibodies to human tumor necrosis factor," <i>J. of Immun. Methods</i> , 96:57-62 (1987).
	AW	Piguet, Pierre-Francois et al., "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," <i>J. Exp. Med.</i> , 166:1280-1289 (1987).
	AX	Meager, Anthony et al., "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," <i>Hybridoma</i> , 6(3):305-311 (1987).
	AY	Fendly, Brian M. et al., "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," <i>Hybridoma</i> , 6(4):359-370 (1987).
	AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," <i>Hybridoma</i> , 6(5):489-507 (1987).
✓	AR2	Tracey, Kevin J. et al., "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," <i>Nature</i> , 330:662-664 (1987).
KAC	AS2	Nagai, M. et al., "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," <i>Experientia</i> , 44:606-607 (1988).

EXAMINER

DATE CONSIDERED

9/7/99 3/14/01


FORM PTO-1449 (REV. 7-80)		ATTY. DOCKET NO. NYU93-01M4AZ		SERIAL NO. 09/133,119	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets, if necessary)		APPLICANT Junming Le et al.		FILING DATE August 12, 1998	
SEP 11 1998		GROUP 1642			
FOREIGN PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS SUB- CLASS TRANSLATION YES NO
KAC	AL3	WO92/13095	06 AUG 92	PCT	
KAC	AM3	0260610A2	23 MAR 88	EPO	X
KAC	AN3	91/09967	11 JUL 91	PCT	
KAC	AO3	0351789A2	24 JAN 90	EPO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
KAC	AT2	Shimamoto, Yoshinori et al., "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," <i>Immunology Letters</i> , 17:311-318 (1988).			
	AU2	Di Giovine, Francesco, S. et al., "Tumour necrosis factor in synovial exudates," <i>Annals of the Rheumatic Diseases</i> , 47:768-772 (1988).			
	AV2	Collins, M.S. et al., "Immunoprophylaxis of Polymicrobial Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of <i>Pseudomonas aeruginosa</i> ," Abstract E-63, <i>Abstracts of Annual Meeting 1989</i> .			
	AW2	Exley, A.R. et al., "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," <i>Medical Research Society</i> , Abstract 184, p. 50 (1989).			
	AX2	Cross, A.S. et al., "Pretreatment with Recombinant Murine Tumor Necrosis Factor $\alpha$ /Cachectin and Murine Interleukin 1 $\alpha$ Protects Mice from Lethal Bacterial Infection," <i>J of Exp Med.</i> , 169:2021-2027 (1989).			
	AY2	Engelmann, Hartmut et al., "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," <i>J. of Bio. Chem.</i> , 264(20):11974-11980 (1989).			
	AZ2	Kawasaki, Hajime et al., "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," <i>Infection and Immunity</i> , 57(10):3131-3135 (1989).			
KAC	AR3	Fong, Yuman et al., "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1 $\beta$ and Interleukin 6 Appearance During Lethal Bacteremia," <i>J. Exp. Med.</i> , 170:1627-1633 (1989).			
EXAMINER		DATE CONSIDERED			

IN AN APPLI

Use several sheets

SEP 11 1998

OFFICE OF  
PATENT & TRADEMARK

FORM PTO-1449 (REV. 7-80)		ATTY. DOCKET NO. NYU93-01M4AZ		SERIAL NO. 09/133,119	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets, if necessary)		APPLICANT Junming Le et al.			
		FILING DATE August 12, 1998		GROUP 1642	
FOREIGN PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
KAL	AZ3	Nophar, Yaron et al., "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," <i>The EMBO Journal</i> , 9(10):3269-3278 (1990).			
	AR4	Engelmann, Hartmut et al., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," <i>J. of Bio. Chem.</i> , 265(3):1531-1536 (1990).			
	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," <i>Eur. J. Clin. Microbiol. Dis.</i> , 9(4):247-250 (1990).			
	AT4	Loetscher, Hansruedi et al., "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," <i>Cell</i> , 61:351-359 (1990).			
	AU4	Schall, Thomas J. et al., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," <i>Cell</i> , 61:361-370 (1990).			
	AV4	Akama, Hideto et al., "Mononuclear Cells Enhance Prostaglandin E <sub>2</sub> Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor $\alpha$ ," <i>Biochemical and Biophysical Research Comm.</i> , 168(2):857-862 (1990).			
	AW4	Exley, A.R. et al., "Monoclonal antibody to TNF in severe septic shock," <i>The Lancet</i> , 335:1275-1277 (1990).			
V	AX4	Möller, Achim et al., "Monoclonal Antibodies to Human Tumor Necrosis Factor $\alpha$ : In Vitro and In Vivo Application," <i>Cytokine</i> , 2(3):162-169 (1990).			
KAL	AY4	Ruddle, Nancy H. et al., "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," <i>J. Exp. Med.</i> , 172:1193-1200 (1990).			
EXAMINER		DATE CONSIDERED			
N. G. J. Korman		9/2/99 3/14/01			

FORM PTO-1449 (REV. 7-80)		ATTY. DOCKET NO. NYU93-01M4AZ		SERIAL NO. 09/133,119		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION  (Use several sheets if necessary)		APPLICANT Junming Le et al.				
		FILING DATE August 12, 1998		GROUP 1642		
SEP 11 1998 FOREIGN PATENT DOCUMENTS						
EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
KAL	AZ4	Galloway, Cynthia J. et al., "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," <i>J. of Immunological Methods</i> , 140:37-43 (1991).				
	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," <i>Science</i> , 252:1657-1662 (1991).				
	AS5	Aderka, Dan et al., "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," <i>Israel J. Med. Sci.</i> , 28(2):126-130 (1992).				
	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," <i>ASM News</i> , 58(9):479-482 (1992).				
	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," <i>TBTECH</i> , 11:42-44 (1993).				
	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," <i>N.E. Journal of Medicine</i> , 328(20):1471-1477 (1993).				
	AW5	Aggarwal, Bharat B. et al., "Human Tumor Necrosis Factor Production, Purification and Characterization," <i>J. of Biol. Chem.</i> , 260(4):2345-2354 (1985).				
KAL	AX5	Beutler, B. et al., "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," <i>J. Exp. Med.</i> , 161:984-995 (1985).				
EXAMINER		N. G. J. Karen G. Gamella		DATE CONSIDERED		9/7/99 3/14/01

FORM PTO-1449  
(REV. 7-80)

ATTY. DOCKET NO.

NYU93-01M4AZ

SERIAL NO.

09/133,119

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

APPLICANT

Junming Le et al.

FILING DATE

August 12, 1998

GROUP

1642

SEP 11 1998

## FOREIGN PATENT DOCUMENTS

EXAM- INER INI- TIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

KAL	AY5	Echtenacher, Bernd et al., "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," <i>J. of Immunology</i> , 145(11):3762-3766 (1990).
KAL	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," Abstract, <i>Endotoxemia &amp; Sepsis Conference</i> (1991).
KAL	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, <i>Endotoxemia &amp; Sepsis Conference</i> (1991).

EXAMINER

DATE CONSIDERED

9/7/99 3/14/01